Eledon Pharmaceuticals, Inc.

NASDAQ•ELDN

CEO: Dr. David-Alexandre C. Gros M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2014-09-17

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

連絡先情報

19900 MacArthur Boulevard, Suite 550, Irvine, CA, 92612, United States

949-238-8090

eledon.com

時価総額

$161.26M

PER (TTM)

-2.6

17.9

配当利回り

52週高値

$4.60

52週安値

$1.35

52週レンジ

41%

順位48Top 64.4%

3.3

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 3.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.23-121.55%

直近4四半期の推移

フリーCF

-$14.48M+23.01%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

R&D Spending Increased Research and development expenses rose $14.74M to $48.78M for nine months ended September 30, 2025, supporting clinical trials.

Warrant Liability Decreased Fair value of warrant liabilities fell $22.92M to $21.95M, reflecting stock price decline and recognized as income.

Recent Financing Secured Successfully closed November 2025 offering, raising approximately $53.6M in net proceeds to fund future operations and development.

Net Loss Widened Nine months net loss reached $35.17M, reversing prior period's $8.43M net income due to operational costs.

リスク要因

Continued Operating Losses Expect recurring net losses for several years; requires substantial additional capital to fund ongoing research and development activities.

Clinical Development Uncertainty Product candidates are in early stages; failure to successfully develop or gain approval will materially harm business prospects.

Significant Stock Dilution Need for future capital raises via equity or debt risks significant dilution to existing common stockholders' ownership interests.

Material Weakness Persists Disclosure controls and procedures were not effective due to an unresolved material weakness in internal control over financial reporting.

見通し

Kidney Program Prioritization Strategy focuses on advancing tegoprubart for kidney transplant rejection; ALS development requires specific additional financing to continue.

Cash Runway Projection Current cash resources are estimated sufficient to meet anticipated cash needs for at least the next 12 months.

Seek Additional Capital Anticipates needing additional financing beyond 12 months via equity, debt, or strategic collaborations to fund future operations.

Advance Regulatory Filings Plans to continue clinical development, manufacturing scale-up, and seek marketing approval for product candidates in key indications.

同業比較

売上高 (TTM)

PBYI

$228.42M

-0.9%

VNDA

$216.11M

+8.7%

EDIT

$40.52M

+25.4%

粗利益率 (最新四半期)

APLT

100.0%

+0.0pp

EDIT

96.7%

+2621.3pp

VNDA

93.3%

+0.1pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ALLO	$539.35M	-2.8	-57.1%	18.0%
VNDA	$520.74M	-2.4	-49.2%	2.6%
TRDA	$485.83M	-3.7	-39.8%	13.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日

EPS:-$0.20

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし